Parkinson’s disease
Conditions
Interventions
Parkinson’s disease:propofol and remifentanil
Non-Parkinson’s disease:propofol and remifentanil
Sponsors
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
Eligibility
Sex/Gender
Male
Age
40 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. PD patients undergoing DBS insertion and pulse generator placement or non-PD patients undergoing intracranial surgery 2. Aged 40-64 years; 3. male.
Exclusion criteria
Exclusion criteria: 1. An ASA score higher than class III; 2. BMI>30kg/m2; 3. predicted difficult airway; 4. alcohol or drug abusers; 5. reactive airway disease or signs of upper respiratory infection; 6. patients who have a high risk of gastric aspiration upon anaesthesia induction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median effective effect-site concentration of remifentanil for I-gel insertion; | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate;Mean arterial pressure;BIS; | — |
Countries
China
Contacts
Public ContactJuan Li
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
Outcome results
None listed